KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab plus lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

被引：0
|
作者：
Kramer, Gero
Shore, Neal D.
Joshua, Anthony M.
Li, Xin Tong
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
Yu, Evan Y.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[3] St Vincents Hosp Sydney, Sydney, NSW, Australia
[4] Merck & Co Inc, Kenilworth, NJ USA
[5] Royal Marsden NHS Fdn Trust, London, England
[6] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS215
引用
收藏
页数：3
相关论文
共 50 条
  • [41] KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
    Hoimes, Christopher J.
    Graff, Julie N.
    Tagawa, Scott T.
    Hwang, Clara
    Kilari, Deepak
    Ten Tije, A. J.
    Omlin, Aurelius
    McDermott, Raymond S.
    Vaishampayan, Ulka N.
    Elliott, Tony
    Gerritsen, Winald R.
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Todenhofer, Tilman
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Byun, Seok-Soo
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [43] Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
    Sridhar, Srikala S.
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Rodriguez, Jose Maria M. Piulats
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony
    Linch, Mark David
    Kolinsky, Michael
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [45] KEYNOTE-365 COHORT C: PEMBROLIZUMAB plus ENZALUTAMIDE IN PATIENTS WITH ABIRATERONE ACETATE-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)-DATA AFTER MINIMUM OF 22 MONTHS OF FOLLOW-UP
    Appleman, Leonard
    Todenhoefer, Tilman
    Berry, William
    Gurney, Howard
    Retz, Margitta
    Conter, Henry
    Laguerre, Brigitte
    Fong, Peter
    Ferrario, Cristiano
    Gravis, Gwenaelle
    Piulats, Josep
    Emmenegger, Urban
    Shore, Neal
    Romano, Emanuela
    Mourey, Loic
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A374 - A374
  • [46] Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
    Conter, Henry Jacob
    Shore, Neal D.
    Berry, William R.
    Fong, Peter C. C.
    Rodriguez, Jose Maria M. Piulats
    Appleman, Leonard Joseph
    Todenhoefer, Tilman
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641
    Graff, Julie Nicole
    Burgents, Joseph
    Liang, Li Wen
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [49] Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
    Yu, Evan Y.
    Joshua, Anthony M.
    Kramer, Gero
    Shore, Neal D.
    Hu, Haixia
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS249 - TPS249
  • [50] KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)-New data after an additional 1 year of follow-up.
    Appleman, Leonard Joseph
    Kolinsky, Michael Paul
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    De Bono, Johann S.
    Boegemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Massard, Christophe
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Li Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345